MX384394B - Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas. - Google Patents

Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas.

Info

Publication number
MX384394B
MX384394B MX2018006631A MX2018006631A MX384394B MX 384394 B MX384394 B MX 384394B MX 2018006631 A MX2018006631 A MX 2018006631A MX 2018006631 A MX2018006631 A MX 2018006631A MX 384394 B MX384394 B MX 384394B
Authority
MX
Mexico
Prior art keywords
compound
prevention
treatment
neurodegenerative diseases
directed
Prior art date
Application number
MX2018006631A
Other languages
English (en)
Other versions
MX2018006631A (es
Inventor
Marco Sealey
Robert Konrat
Original Assignee
Univ Wien
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP16156775.5A external-priority patent/EP3207925A1/en
Application filed by Univ Wien filed Critical Univ Wien
Publication of MX2018006631A publication Critical patent/MX2018006631A/es
Publication of MX384394B publication Critical patent/MX384394B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a un compuesto para uso en la prevención o tratamiento de una enfermedad neurodegenerativa, en particular de una sinucleinopatía. La presente invención además está dirigida a una composición farmacéutica que contiene una cantidad efectiva de dicho compuesto y uno o más auxiliares farmacéuticamente aceptables.
MX2018006631A 2015-11-30 2016-11-30 Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas. MX384394B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15196984 2015-11-30
EP16156775.5A EP3207925A1 (en) 2016-02-22 2016-02-22 Compound for use in the prevention and treatment of neurodegenerative diseases
PCT/EP2016/079353 WO2017093363A1 (en) 2015-11-30 2016-11-30 Compound for use in the prevention and treatment of neurodegenerative diseases

Publications (2)

Publication Number Publication Date
MX2018006631A MX2018006631A (es) 2019-01-30
MX384394B true MX384394B (es) 2025-03-14

Family

ID=57539219

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018006631A MX384394B (es) 2015-11-30 2016-11-30 Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas.

Country Status (14)

Country Link
US (1) US11179358B2 (es)
EP (2) EP3735965A1 (es)
JP (2) JP7033073B2 (es)
CN (1) CN108601758A (es)
AU (1) AU2016364308B2 (es)
CA (1) CA3003841A1 (es)
DK (1) DK3383381T3 (es)
ES (1) ES2804541T3 (es)
HU (1) HUE050096T2 (es)
IL (1) IL259383B (es)
MX (1) MX384394B (es)
PT (1) PT3383381T (es)
SG (2) SG11201803422RA (es)
WO (1) WO2017093363A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114302885A (zh) * 2019-06-18 2022-04-08 维也纳大学 杯芳烃化合物及其用途
WO2024112103A1 (ko) * 2022-11-22 2024-05-30 경북대학교 산학협력단 신경염증성 질환 치료효과를 나타내는 신규 펩타이드 및 이의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489612A (en) 1991-08-23 1996-02-06 The University Of Alabama At Birmingham Research Foundation Calixarene chloride-channel blockers
FR2782007B1 (fr) 1998-08-05 2001-02-23 Centre Nat Rech Scient Utilisation des calix(n)arenes pour le traitement des maladies fibrotiques
US8506959B2 (en) * 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
ZA200701531B (en) * 2004-08-09 2009-03-25 Elan Pharm Inc Prevention and treatment of synucleinopathic and amyloidogenic disease
FR2888937B1 (fr) * 2005-07-21 2012-10-26 Biomerieux Sa Procede de detection des fcpa utilisant un agent d'agregation des fcpa et un agent de capture des agregats formes
JP5654748B2 (ja) * 2006-03-29 2015-01-14 ウイスタ・ラボラトリーズ・リミテッドＷｉｓｔａ Ｌａｂｏｒａｔｏｒｉｅｓ Ｌｔｄ． タンパク質凝集の阻害物質
WO2013134371A1 (en) 2012-03-06 2013-09-12 Neuropore Therapies, Inc. Methods and compounds to be used in the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
JP2018535272A (ja) 2018-11-29
SG11201803422RA (en) 2018-06-28
AU2016364308A1 (en) 2018-05-17
EP3383381B1 (en) 2020-04-08
US11179358B2 (en) 2021-11-23
CN108601758A (zh) 2018-09-28
JP7033073B2 (ja) 2022-03-09
WO2017093363A1 (en) 2017-06-08
IL259383A (en) 2018-07-31
SG10202004908UA (en) 2020-06-29
DK3383381T3 (da) 2020-07-13
EP3735965A1 (en) 2020-11-11
CA3003841A1 (en) 2017-06-08
PT3383381T (pt) 2020-07-03
US20200360315A1 (en) 2020-11-19
AU2016364308B2 (en) 2022-03-10
ES2804541T3 (es) 2021-02-08
HUE050096T2 (hu) 2020-11-30
EP3383381A1 (en) 2018-10-10
IL259383B (en) 2022-07-01
JP2022027864A (ja) 2022-02-14
MX2018006631A (es) 2019-01-30

Similar Documents

Publication Publication Date Title
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
CR20180496A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP16008797A (es) Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos
BR112018005905A2 (pt) ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto?
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
EA201692470A1 (ru) Фармацевтические комбинации
EA201790276A1 (ru) Новые имидазопиридазиновые соединения и их применение
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
MX2021010041A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
EA201791696A1 (ru) Композиция для лечения веноокклюзионной болезни печени
MX388592B (es) Compuestos y metodos terapeuticos.
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
BR112018006206A2 (pt) composição, uso de uma combinação, forma de dosagem fixa farmacêutica, combinação de dosagem fixa, embalagem, e, uso de uma combinação de dose fixa
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet
BR112017024126B8 (pt) Composições farmacêuticas, composto a micronizado e/ou pelo menos um sal farmaceuticamente aceitável micronizado do composto a e uso dos mesmos
UA116499C2 (uk) (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
CL2017002229A1 (es) Inhibidores de bace1.
MX384394B (es) Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas.
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
EA201501130A1 (ru) Офтальмологическая фармацевтическая композиция
MX2017011904A (es) Composiciones para el tratamiento de fibrosis y afecciones relacionadas con fibrosis.
MX2019009909A (es) Composiciones farmaceuticas para terapia de combinacion.